Answers are grounded in this paper and cite their sources.
The 20th century was one of relative confidence regarding pregnancy in women with underlying rheumatoid arthritis (RA). Beginning in the 1930s, when P.S. Hench first reported the amelioration of RA symptoms during pregnancy [1], several subsequent studies have confirmed high rates of symptom improvement (approaching 75%) or even remission of maternal disease during gestation, with a characteristic worsening in the postpartum period [2-4]. Most of these studies were performed at single centres with a relatively low numbers of patients. Many, although not all, were based on retrospective data that is invariably subject to recall bias. Standardized measures of disease activity were not developed or universally employed. Nonetheless, the results were strikingly consistent and reassuring. A series of thoughtful and interesting studies sought to better understand the small subset of RA patients who did not achieve substantial improvement or even suffered worsening of disease during pregnancy [5-7]; however, no clinical, laboratory, or even genetic markers have been conclusively identified thus far. Barring a few reports [2, 4] there was little corresponding study of pregnancy outcomes in women with RA. Presumably, it was assumed that if pregnancy did not pose an undue risk to the mother regarding disease activity, then pregnancies were likely to be safe and low-risk overall. Additionally, reports of adverse pregnancy outcomes in RA patients were not nearly as dramatic as reports of pregnancy outcomes amongst women with lupus which were fraught with maternal and foetal demise, flares of severe maternal disease and preeclampsia. Therefore, we ended the 20th century with a sense of ease regarding treatments and outcomes for the pregnant RA patient in stark contrast to the caution and hesitancy towards the pregnant lupus patient. One unintended consequence of the RA pregnancy data was a tendency to discourage active anti-rheumatic therapy in women who became pregnant or who sought counselling regarding a future pregnancy. Certainly, methotrexate, one of the mainstays of disease modifying therapy in the prebiologic era, has widely recognized teratogenic potential. The risk-benefit analysis strongly favoured avoidance of medical therapy as pregnancy itself had comparable, if not superior, efficacy to the commonly utilized medical regimens. In contrast, the 21st century brought renewed interest in studying pregnancy outcomes amongst women with RA, with results challenging previously held assumptions. Reasons for this renewed interest are multifactorial and include (i) the development of novel therapeutic agents for RA which called for the study of teratogenicity associated with inadvertent antenatal exposure, (ii) better disease control with the use of newer medications which has allowed women to feel more capable of raising young children despite underlying RA and (iii) the ongoing scientific quest to better understand the immunobiology of disease amelioration during the natural immunologic modulation of pregnancy. Simultaneously, it was recognized that the incidence of pregnancy in RA at any given centre was insufficient to generate statistically meaningful sample sizes. Therefore, multicentre or nationwide studies to more conclusively examine the interactions between pregnancy and RA have been necessary. Prospective multicentre studies have been published from several countries including the UK [8] and the Netherlands [9]. Results from these studies have challenged previous reports suggesting that the majority of patients experienced improvement or remission in disease activity. Older studies have approximated that 75% of pregnant women experience improvement. Newer studies have suggested that a smaller proportion experience improvement (48–66%), and only a minority (16–25%) of patients reach remission by the third trimester [8, 9]. Furthermore, recent data has associated disease activity during pregnancy with slightly lower birthweight and delivery at earlier gestational ages. This suggests, but does not confirm, that improved control of inflammation during pregnancy may lead to improved pregnancy outcomes. In addition to larger, multicentre prospective observational studies of disease activity during pregnancy, several studies have been recently published examining nationwide pregnancy outcomes of women with RA utilizing administrative datasets from the United States [10, 11], Taiwan [12], and the study published in this issue from Sweden and Denmark [13]. These studies all concur that maternal RA is associated with increased risks of several adverse pregnancy outcomes. These include low birth weight infants, premature delivery, intrauterine growth restriction and preeclampsia. Relative risks of adverse outcomes in RA were not of the magnitude seen in pregnant women with lupus or diabetes mellitus [11], but were consistent across three different populations. Adjusted odds ratios for small for gestational age infants ranged from 1.20 to 1.56 [10, 12, 13], intrauterine growth restriction of 2.2 [11], preterm delivery from 1.17 to 1.78 [10, 12, 13] and preeclampsia from 1.4 to 2.2 [10-12]. These data collectively challenge earlier beliefs that pregnancy in the RA patient lead to near uniform improvement in symptoms without demonstrable risk to the pregnancy. Clearly, the risk-benefit analysis of medical therapy during pregnancy has begun to shift. Unfortunately, an important limitation inherent in all of the studies utilizing administrative databases is the absence of data regarding measures of disease activity and of medication use prior to or during the pregnancy. Even when these data are available [14], they are interrelated in such a way that separating individual effects are difficult. The study by Noorgard et al. [13] is an excellent example of trying to understand the role of disease activity in pregnancy outcomes whilst working within the confines of available administrative data. By limiting the study to primigravidas with singleton deliveries, important confounders associated with previous pregnancies, parity and multiple gestations were eliminated. Smoking and markers of socioeconomic status were included in multivariate models; both are associated with increased disease activity and with adverse pregnancy outcomes. Two surrogate measures of RA severity were employed: rheumatoid factor seropositivity and recent history of RA-related orthopaedic procedures. The former is a biomarker generally associated with more aggressive disease and extra-articular manifestations. Seropositive patients represent a group that may be less likely to improve during pregnancy [15]. The latter may be a marker of both disease severity and duration (keeping in mind that the mean age of women in the study is 31 years). Indeed, there appears to be a dose-dependent relationship to outcomes – higher risks of adverse pregnancy outcomes with seropositivity and with recent RA-related orthopaedic procedures. This report supports prospective data associating active maternal disease with adverse pregnancy outcomes. Perhaps one of the most interesting results from this study is the analysis of congenital malformations in infants born to mothers with RA. Concern for teratogenic potential is amongst the most important reasons why medications are avoided during pregnancy. Not only were data on absolute numbers of congenital malformations available in this study, but data on specific defects were provided to evaluate for patterns of anomalies. A total of 51 infants born to 1199 mothers with RA had congenital anomalies (<5% incidence); two (0.16%) infants had limb reduction defects and five (0.42%) had cleft lip/palate. These two specific anomalies have been associated with antenatal exposure to methotrexate and to prednisone. Rates of other specific congenital malformations were not different between RA and control groups. Although data from medication exposure were not available, analysis of congenital malformations by calendar year through a decade that experienced dramatic changes in treatment practices (inversion of the treatment pyramid [16] and widespread use of biologic therapies and combination regimens) yielded very thought-provoking results. All of the increased risk of congenital anomalies reported in the paper occurred during 1994–1997, prior to approval of leflunomide or any biologic agents for RA. There was no increased risk during 1998–2006 as therapeutic options increased dramatically for patients. This trend is unlikely to be a result of profound and systematic improvements in preconceptional counselling to avoid pregnancy whilst taking teratogenic medications in combination with an overwhelming reduction in unintended pregnancies. Where do we go from here? It will likely never be clear whether adverse pregnancy outcomes (including congenital malformations) are due to underlying disease activity, medical treatment, or a combination of the two. These data may never exist [17]. We do know that the situation is more complex than what we believed 20 years ago. Data are increasingly suggestive that higher disease activity plays a role in pregnancy outcomes. We also recognize that women rely on physicians for guidance regarding use of medications during pregnancy and we must be prepared to discuss the uncertainties that surround the risks and benefits of these drugs. The risk-benefit analysis of medication use in pregnancy should be balanced and focus not only on risks of medication exposure (teratogenic and other) but on risks to the mother and foetus of undertreated maternal disease. Certainly, medications with known teratogenic potential should always be avoided, but others have a more favourable safety profile and need to be considered for the treatment of active disease [18]. None. No conflicts of interest to declared.
No takes yet. Share an insight, caveat, or question.
Eliza F. Chakravarty (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: